Dev122408 2329..2337
نویسندگان
چکیده
When a tubular structure forms during early embryogenesis, tubular elongation and lumen formation (epithelialization) proceed simultaneously in a spatiotemporally coordinated manner. We here demonstrate, using the Wolffian duct (WD) of early chicken embryos, that this coordination is regulated by the expression of FGF8, which shifts posteriorly during body axis elongation. FGF8 acts as a chemoattractant on the leader cells of the elongating WD and prevents them from epithelialization, whereas static (‘rear’) cells that receive progressively less FGF8 undergo epithelialization to form a lumen. Thus, FGF8 acts as a binary switch that distinguishes tubular elongation from lumen formation. The posteriorly shifting FGF8 is also known to regulate somite segmentation, suggesting that multiple types of tissue morphogenesis are coordinately regulated by macroscopic changes in body growth.
منابع مشابه
VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.
PURPOSE We aim to characterize VTX-2337, a novel Toll-like receptor (TLR) 8 agonist in clinical development, and investigate its potential to improve monoclonal antibody-based immunotherapy that includes the activation of natural killer (NK) cells. EXPERIMENTAL DESIGN HEK-TLR transfectants were used to compare the selectivity and potency of VTX-2337, imiquimod, CpG ODN2006, and CL075. The abi...
متن کاملTLR8 agonist VTX-2337 enhances NKG2D-mediated cytotoxicity of NK cells
NK cells express an array of activating and inhibitory receptors, which facilitate the recognition and lysis of virally infected and transformed cells, but safeguard healthy cells from attack. NKG2D is an activating receptor expressed on the surface of NK cells that recognizes the ligands MICA/B and ULBP in human, which can be expressed on tumor cells or virus-infected cells. While NKG2D-mediat...
متن کاملAugments ADCC VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Updated Version
Purpose: We aim to characterize VTX-2337, a novel Toll-like receptor (TLR) 8 agonist in clinical development, and investigate its potential to improve monoclonal antibody–based immunotherapy that includes the activation of natural killer (NK) cells. Experimental Design:HEK-TLR transfectants were used to compare the selectivity and potency of VTX2337, imiquimod, CpGODN2006, andCL075. The ability...
متن کاملCancer Therapy: Preclinical VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
Purpose: We aim to characterize VTX-2337, a novel Toll-like receptor (TLR) 8 agonist in clinical development, and investigate its potential to improve monoclonal antibody–based immunotherapy that includes the activation of natural killer (NK) cells. Experimental Design:HEK-TLR transfectants were used to compare the selectivity and potency of VTX2337, imiquimod, CpGODN2006, andCL075. The ability...
متن کاملCoordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity
UNLABELLED VTX-2337 (USAN: motolimod) is a selective toll-like receptor 8 (TLR8) agonist, which is in clinical development as an immunotherapy for multiple oncology indications, including squamous cell carcinoma of the head and neck (SCCHN). Activation of TLR8 enhances natural killer cell activation, increases antibody-dependent cell-mediated cytotoxicity, and induces Th1 polarizing cytokines. ...
متن کامل